Silicon Valley startup, Level 42 AI, Inc’s software-defined hardware captures and synchronizes traditionally discarded or unobserved multi-modal data streams to predict and quantify health state, from short 5-to-30 second data snippets, similar in principle to the music identification Shazam app. UNMET NEED: In addition to the ‘classic‘ COVID-19 illness, COVID-19-associated multi-system inflammatory syndrome in children (MIS-C) has recently emerged as a complicated and potentially fatal outcome resulting in school and workplace closures. The world needs a fast, accurate, non-invasive, affordable mass screening test for COVID-19; such a test should safely manage entry to workplaces, airplanes, schools, stadiums, theaters, mass transit center, ports-of-entry, malls and restaurants. Level 42 AI, Inc is conducting clinical studies to discover and validate COVID-19 biosignatures with Johns Hopkins School of Medicine (JHM) and University of California-San Francisco (UCSF). The mass screening technology has the potential to detect and screen individuals and patients with COVID-19 remotely, from a distance, using non-invasive, non-intrusive, and non-contact technology. Accurate and rapid COVID-19 mass screening is complementary to vaccine development and deployment. Level 42 AI, Inc’s COVID-19 biosignature is an AI algorithm that deploys state-of-the-art, proprietary domain-adaptable machine learning techniques to elucidate and differentiate early cellular and tissue mechano-transduction changes and the body's immune response to SARS-CoV-2 infection. By combining and analyzing multiple synchronized data streams, Level 42 AI, Inc aims to unveil robust and distinct biosignatures for actionable insights on the symptoms and onset of COVID-19, MIS-C, asthma, COPD, cystic fibrosis, TB, pulmonary arterial hypertension, acute respiratory distress syndrome, carotid artery disease, coronary artery disease, congestive heart failure, pain, depression, more